CA2320928C - Nanoparticules comprenant un poly(cyanoacrylate d'alkyl) et un oligosaccharide cyclique - Google Patents

Nanoparticules comprenant un poly(cyanoacrylate d'alkyl) et un oligosaccharide cyclique Download PDF

Info

Publication number
CA2320928C
CA2320928C CA002320928A CA2320928A CA2320928C CA 2320928 C CA2320928 C CA 2320928C CA 002320928 A CA002320928 A CA 002320928A CA 2320928 A CA2320928 A CA 2320928A CA 2320928 C CA2320928 C CA 2320928C
Authority
CA
Canada
Prior art keywords
nanoparticles
active
polymerization
active ingredient
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002320928A
Other languages
English (en)
French (fr)
Other versions
CA2320928A1 (fr
Inventor
Airton Monza Da Silveira
Gilles Ponchel
Dominique Duchene
Patrick Couvreur
Francis Puisieux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioalliance Pharma SA
Original Assignee
Bioalliance Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma SA filed Critical Bioalliance Pharma SA
Publication of CA2320928A1 publication Critical patent/CA2320928A1/fr
Application granted granted Critical
Publication of CA2320928C publication Critical patent/CA2320928C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA002320928A 1998-02-27 1999-02-24 Nanoparticules comprenant un poly(cyanoacrylate d'alkyl) et un oligosaccharide cyclique Expired - Fee Related CA2320928C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR98/02429 1998-02-27
FR9802429A FR2775435B1 (fr) 1998-02-27 1998-02-27 Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
PCT/FR1999/000418 WO1999043359A1 (fr) 1998-02-27 1999-02-24 Nanoparticules comprenant polyisobutylcyanoacrylate et cyclodextrines

Publications (2)

Publication Number Publication Date
CA2320928A1 CA2320928A1 (fr) 1999-09-02
CA2320928C true CA2320928C (fr) 2009-12-15

Family

ID=9523473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002320928A Expired - Fee Related CA2320928C (fr) 1998-02-27 1999-02-24 Nanoparticules comprenant un poly(cyanoacrylate d'alkyl) et un oligosaccharide cyclique

Country Status (12)

Country Link
US (1) US6881421B1 (https=)
EP (1) EP1056477B1 (https=)
JP (1) JP4651192B2 (https=)
AT (1) ATE311906T1 (https=)
AU (1) AU753573B2 (https=)
CA (1) CA2320928C (https=)
DE (1) DE69928776T2 (https=)
DK (1) DK1056477T3 (https=)
ES (1) ES2255246T3 (https=)
FR (1) FR2775435B1 (https=)
IL (2) IL137882A0 (https=)
WO (1) WO1999043359A1 (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582713B2 (en) 2000-04-06 2003-06-24 Univ. Of Colorado - Colorado Springs Compositions and methods for promoting wound healing
FR2808691B1 (fr) * 2000-05-12 2005-06-24 Coletica Cyclodextrines substituees preferentiellement sur leur face primaire par des fonctions acide ou amine
FR2816949B1 (fr) * 2000-11-17 2003-11-28 Centre Nat Rech Scient Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
US6890703B2 (en) 2002-03-06 2005-05-10 International Business Machines Corporation Preparation of crosslinked particles from polymers having activatible crosslinking groups
EP1494649B1 (en) * 2002-04-12 2012-01-04 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
FR2841137B1 (fr) * 2002-06-20 2004-08-13 Bioalliance Pharma Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
US20050255164A1 (en) * 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
US20050051968A1 (en) * 2002-11-13 2005-03-10 Froesel David William Washer toss game
EP1761283A2 (en) * 2004-06-07 2007-03-14 California Institute Of Technology Biodegradable drug-polymer delivery system
FR2872703B1 (fr) * 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
ATE419842T1 (de) * 2004-09-14 2009-01-15 Nanodel Technologies Gmbh Abgabevehikel mit nanoteilchen
WO2006038552A1 (ja) * 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. 微粒子含有組成物およびその製造方法
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
KR100726720B1 (ko) 2005-12-26 2007-06-11 코스맥스 주식회사 수난용성 활성물질을 하이드록시알킬화 사이클로덱스트린과리포좀으로 이중 안정화 시킨 나노캡슐 리포좀 조성물
BRPI0713533A2 (pt) * 2006-06-26 2012-04-17 Mutual Pharmaceutical Co formulações de agente ativo, métodos de fabricação, e métodos de uso
US8679539B2 (en) * 2007-01-31 2014-03-25 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
JP5224313B2 (ja) * 2007-02-27 2013-07-03 公立大学法人横浜市立大学 プラスミド送達用粒子
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US9132296B2 (en) 2007-05-17 2015-09-15 Ag Essence Antimicrobial solution and methods of making and using the same
US8729121B2 (en) * 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
EP2742875B1 (en) * 2007-11-14 2016-02-24 Adhezion Biomedical, LLC Cyanoacrylate tissue adhesives
JP5618284B2 (ja) 2007-12-27 2014-11-05 昇一 城武 グラム陽性細菌用抗菌剤
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US8293838B2 (en) * 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US20110117047A1 (en) 2008-06-23 2011-05-19 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
EP2153821A1 (en) 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
US8609128B2 (en) * 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
PL2434886T3 (pl) 2009-05-29 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje do wstrzykiwania melfalanu zawierające pochodną cyklodekstryny i sposoby ich wytwarzania i stosowania
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
CA2798739A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
AU2012233439A1 (en) 2011-03-31 2013-11-14 Nanocame Co., Ltd. Novel preparation technique for higher-order structure that exhibits anti-cellular effect
PL2508207T3 (pl) * 2011-03-31 2013-09-30 Bioalliance Pharma Nanocząsteczki zawierające chemioterapeutyczny lek przeciwnowotworowy
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
KR20140050698A (ko) 2011-07-29 2014-04-29 셀렉타 바이오사이언시즈, 인크. 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체
JP2015501197A (ja) 2011-09-23 2015-01-15 エメラルド・ヒルトン・デイビス，エルエルシー 自己組織化ナノ構造粒子およびその調製方法
US10988618B2 (en) 2011-09-23 2021-04-27 Dystar Hilton Davis Corp. Self-assembled nano-structured particle and methods for preparing
EP2805617A4 (en) * 2012-01-19 2015-08-12 Shoichi Shirotake ANTIBACTERIAL AGENT AGAINST BACTERIA CAUSING PLANT DISEASE
CN102579402B (zh) * 2012-03-26 2013-07-03 山东大学 一种负载紫杉醇的囊泡的制备方法
US11547116B2 (en) 2012-12-12 2023-01-10 William Wingfield Metal oxide compounds and infusion into polymer compounds
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
US10351644B2 (en) 2014-02-27 2019-07-16 Shoichi Shirotake Antiviral drug
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
WO2017046037A1 (en) 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
WO2017144548A1 (en) 2016-02-22 2017-08-31 Onxeo Combination therapies comprising immuno-oncology agents and doxorubicin-loaded poly(cyanoacrylate) nanoparticles
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
DK4257600T3 (da) 2018-07-03 2025-05-26 Gilead Sciences Inc Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem
JP7490925B2 (ja) 2018-07-26 2024-05-28 エータイアー ファーマ， インコーポレイテッド Ｎｒｐ２関連疾患を治療するための組成物および方法
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
DK4037708T3 (da) 2019-09-30 2024-09-30 Gilead Sciences Inc HBV-vacciner og fremgangsmåder til at behandle HBV
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504408B1 (fr) * 1981-04-24 1986-02-14 Couvreur Patrick Procede de preparation de particules submicroscopiques, particules ainsi obtenues et compositions pharmaceutiques les contenant
US5246611A (en) * 1990-05-09 1993-09-21 The Procter & Gamble Company Non-destructive carriers for cyclodextrin complexes
EP0548157B1 (en) * 1990-09-14 1998-05-20 Syngenix Limited Use of particulate agents
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
DE69432867T2 (de) * 1993-11-18 2004-04-22 Sirtex Medical Ltd., Burswood Zubereitung mit gesteuerter freisetzung
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin

Also Published As

Publication number Publication date
AU2628799A (en) 1999-09-15
US6881421B1 (en) 2005-04-19
FR2775435A1 (fr) 1999-09-03
JP2002504526A (ja) 2002-02-12
FR2775435B1 (fr) 2000-05-26
WO1999043359A1 (fr) 1999-09-02
EP1056477A1 (fr) 2000-12-06
IL137882A (en) 2006-12-31
DE69928776T2 (de) 2006-09-07
DE69928776D1 (de) 2006-01-12
IL137882A0 (en) 2001-10-31
DK1056477T3 (da) 2006-04-18
JP4651192B2 (ja) 2011-03-16
AU753573B2 (en) 2002-10-24
ATE311906T1 (de) 2005-12-15
ES2255246T3 (es) 2006-06-16
CA2320928A1 (fr) 1999-09-02
EP1056477B1 (fr) 2005-12-07

Similar Documents

Publication Publication Date Title
CA2320928C (fr) Nanoparticules comprenant un poly(cyanoacrylate d'alkyl) et un oligosaccharide cyclique
JP2002504526A5 (https=)
Duchêne et al. Cyclodextrins in targeting: application to nanoparticles
Muankaew et al. Cyclodextrin‐based formulations: a non‐invasive platform for targeted drug delivery
Sonaje et al. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats
Cavalli et al. Cyclodextrin-based nanosponges for drug delivery
Krauland et al. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system
Govender et al. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug
Khalil et al. Preparation and evaluation of warfarin-β-cyclodextrin loaded chitosan nanoparticles for transdermal delivery
Nehilla et al. Purified and surfactant-free coenzyme Q10-loaded biodegradable nanoparticles
US7682635B2 (en) Aqueous dispersions of nanometric or micrometric particles for encapsulating chemical compounds
FR2809112A1 (fr) Materiaux a base de polymeres biodegradables et son procede de preparation
WO2003027169A1 (fr) Materiau compose d'au moins un polymere biodegradable et de cyclodextrines
Cavalli et al. Nanoparticles derived from amphiphilic γ-cyclodextrins
Ranjan et al. Preparation, Characterization and Evaluation of Resveratrol Loaded Pegylated PLGA Nanoparticles.
Pandey et al. Cyclodextrin based nanoparticles for improved solubility and drug delivery
CA3146881A1 (fr) Structures particulaires a base de nanoparticules d'or, leurs procedes de preparation et leurs utilisations dans le traitement des tumeurs solides
Wang et al. Formulating biomolecular crowns on micelles: a potential strategy for improving micelle stability
Graves et al. The effect of coencapsulation of bovine insulin with cyclodextrins in ethylcellulose microcapsules
Sangeetha et al. Preparation, Characterization and Cytotoxicity Evaluation of Curcuminoid Compound Loaded PLGA Nanoparticles for Chemotherapy of Cancer.
Erdoğar et al. Cyclodextrins in drug delivery
Hu et al. Applications in Pharmaceuticals
Shrivas et al. PREPARATION AND IN-VITRO EVALUATION OF CYCLODEXTRIN NANOSPONGE OF POORLY WATER SOLUBLE DRUG VALDECOXIB
Panchal Preparation, Characterization and Cytotoxicity Evaluation of Curcuminoid Compound Loaded PLGA Nanoparticles for Chemotherapy of Cancer J. Sangeetha", Mubeen G", Parameswari Prabhu", Arman Dalal “, Deblina Sardar", Shiv Kumar Sharma", Himanshu Panchal", Twinkle Kumari"" Department of Pharmacognosy, Mallareddy institute of Pharmaceutical Sciences, Maisammaguda, Dhulapally
Sharma et al. Preparation, Characterization and Cytotoxicity Evaluation of Curcuminoid Compound Loaded PLGA Nanoparticles for Chemotherapy of Cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180226